About Aurion Biotech
Aurion Biotech is a Healthcare company based in Seattle (United States) founded in 2021, and was acquired by Alcon in March 2025. Aurion Biotech is focused on developing advanced therapies for ocular diseases. It operates on a HealthTech model. Aurion Biotech has raised $120 million across 1 funding round from investors including Alcon, KKR and Falcon-Vision. Its chief executive, as recorded, is Greg Kunst. Aurion Biotech offers products and services including Cell Therapy for Corneal Endothelial Disease. Its focus areas include Biotechnology and Cell Therapy. Its legal entity is Aurion Biotech Japan, LLC. Its competitors include ViaCyte, Capricor Therapeutics and Neurona Therapeutics; 2 of its 3 listed competitors have raised funding.
Company details
Aurion Biotech is engaged in the development of innovative therapies aimed at restoring vision. The company operates as a clinical-stage biotech entity with a primary focus on ocular diseases, particularly corneal endothelial dystrophies. A patented cell therapy treatment is being developed as their first candidate to address these conditions. Their work spans across the healthcare sector, emphasizing accessible and effective solutions for patients worldwide.
- Headquarters Seattle, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aurionbiotech.com
- Social LinkedIn Facebook
- Acquired by Alcon (Mar 2025)
- Legal Name Aurion Biotech Japan, Llc
Products & Services of Aurion Biotech
Aurion Biotech offers a comprehensive portfolio of products and services, including Cell Therapy for Corneal Endothelial Disease.
Cell therapy is developed for corneal endothelial diseases.
Funding Insights of Aurion Biotech
Aurion Biotech has successfully raised a total of $120M through 1 strategic funding round. The most recent funding activity was a Series C round of $120 million completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120M
- Total Rounds 1
- Last Round Series C — $120M
- First Round $120M
(Apr 2022)
- Investors Count 7
All 1 funding rounds of Aurion Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2022 | $120M | Series C | – | Deerfield |
7 investors in total: 7 institutional.
Investors in Aurion Biotech
Aurion Biotech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Alcon, KKR and Falcon-Vision.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Petrichor is engaged in supporting healthcare innovation through investments. | 2018 | petrichorcap.com | New York, USA | |
Flying L Partners is focused on ophthalmic sector investments. | flyinglpartners.com | |||
Multiple sectors are invested in by this private equity firm. | 1976 | kkr.com | New York, United States | |
A venture capital fund focused on life sciences investments. | 2019 | visionaryvc.com | Newport Beach, United States | |
Industrial machinery is manufactured and distributed by Falcon-Vision since 1996. | 1996 | falcon-vision.com | Budapest, Hungary | |
Developer of a wide range of eye care products | 1945 | alcon.com | Fort Worth, United States |
Investor details for Aurion Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aurion Biotech
56 people are tracked at Aurion Biotech (22 in leadership, 16 in board & advisors, 18 in team).
| Name | Role | Group |
|---|---|---|
Greg Kunst | CEO | Leadership |
Yugang Chen | Director, Head Of Analytical Development,- Cell Therapy | Leadership |
Pranay Khare | Sr. Director | Leadership |
Eris Jordan | VP, Global Clinical & Medical Affairs | Leadership |
Kelly Hall | Director Of Clinical Development Operations | Leadership |
Andrew Torres | Chief Manufacturing Officer | Leadership |
Brad Andrew Shutzberg | Senior Director, Finance | Leadership |
Kellen Lavigne | Director, Supply Chain & Logistics | Leadership |
Lan le | Executive Director | Leadership |
Arnaud Lacoste, PhD MBA | Chief Executive Officer | Leadership |
Xin Qu | Director of BioEngineering and Delivery | Leadership |
Frada Berenshteyn, MS, MBA | Senior Director, Cellular Therapeutics And Process Design | Leadership |
Jason Freimark | Director Of Information Technology | Leadership |
Don Munoz | Chief Financial Officer | Leadership |
Saba Kadlec | Executive Director Of Clinical Development | Leadership |
Judith Mcgarry | VP, Marketing & Communications | Leadership |
Gwen Anderson | Director, Real Estate and Facilities | Leadership |
Hiromi Urasawa | 安全管理部 部長 Director Of Safety Management,事業本部 部長 Director Of Business Development | Leadership |
Sterling Chung | Vice President, Regulatory Affairs And Quality | Leadership |
Erin Connors | Human Resources Partner | Leadership |
36 more people are available in the full profile.
Complete people profiles for Aurion Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aurion Biotech
3 dated milestones of Aurion Biotech across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Aurion Biotech is founded.
- Funding First funding round of $120.0M.
- Exit Acquired by Alcon.
Competitors of Aurion Biotech
Aurion Biotech has 3 listed competitors in our database, 2 of them funded. They include ViaCyte, Capricor Therapeutics and Neurona Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| capricor.com | 2005 | Los Angeles, United States | 62 | Regenerative medicine for cardiovascular disorders is developed using cell-based platforms. | ||
| neuronatherapeutics.com | 2008 | San Francisco, United States | $417.69M | 67 | Cell-based therapies are developed for intractable neurological diseases. |
Detailed competitors of Aurion Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aurion Biotech
The website of Aurion Biotech (aurionbiotech.com) receives about 4.5K visits a month.
- Monthly visits4.5K
▼ 27.2% vs previous month
Top companies in Cell Therapy
3 companies that operate in the same segment as Aurion Biotech (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aurion Biotech
Complete news archive for Aurion Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurion Biotech
Aurion Biotech was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Aurion Biotech is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Greg Kunst is the CEO of Aurion Biotech, as recorded in our data.
Aurion Biotech is a funded company, having raised a total of $120M across 1 funding round to date. The company's 1st funding round was a Series C of $120M, raised on Apr 2022.
Aurion Biotech is engaged in the development of innovative therapies aimed at restoring vision. The company operates as a clinical-stage biotech entity with a primary focus on ocular diseases, particularly corneal endothelial dystrophies. A patented cell therapy treatment is being developed as their first candidate to address these conditions. Their work spans across the healthcare sector, emphasizing accessible and effective solutions for patients worldwide.
Aurion Biotech's top competitors include Neurona Therapeutics, Capricor Therapeutics and ViaCyte.
Aurion Biotech offers Cell Therapy for Corneal Endothelial Disease.
Aurion Biotech has 7 investors. Key investors include Alcon, KKR, Falcon-Vision, Deerfield, and Petrichor.
Aurion Biotech operates through Aurion Biotech Japan, Llc.
Yes. Aurion Biotech was acquired by Alcon in March 2025.